Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Tips from these results
Recent Share tips:
- Avoid Itaconix (ITX) by Steve Moore in ShareProphets
- Avoid MusicMagpie (MMAG) by Tom Winnifrith in ShareProphets
- Avoid Netcall (NET) by Steve Moore in ShareProphets
- Buy Taylor Wimpey (TW.) by Michael Hawkins in The Motley Fool
- Add Scottish Mortgage Inv Trust (SMT) by Alan Oscroft in The Motley Fool
- Buy Hargreaves Lansdown (HL.) by Gabriel McKeown in The Motley Fool
- Avoid Topps Tiles (TPT) by Steve Moore in ShareProphets
- Buy Tesco (TSCO) by Chris Bailey in ShareProphets
- Buy Anglo American (AAL) by Royston Wild in The Motley Fool
- Buy JD Sports Fashion (JD.) by Christopher Ruane in The Motley Fool
- Buy Legal & General Group (LGEN) by Christopher Ruane in The Motley Fool
- Overweight Imperial Brands (IMB) by JP Morgan
- Overweight Tesco (TSCO) by Barclays
- Equal Weight Sage Group (SGE) by Barclays
- Equal Weight Spirax-Sarco Engineering (SPX) by Barclays
- Equal Weight Halma (HLMA) by Barclays
- Overweight FDM Group (Holdings) (FDM) by Barclays
- Overweight Softcat (SCT) by Barclays
- Overweight Bytes Technology Group (BYIT) by Barclays
- Overweight BP (BP.) by Barclays
Oxford Biomedica (OXB)
Health Care Sector
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
Stock Splits and Consolidations
30/05/2018 – Stock Consolidation 50.000:1.000
Oxford Biomedica Overview
Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.Latest Oxford Biomedica Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | RBC Capital | – | 2022-07-01 07:13:00 01/07/2022 | – |
| – | RBC Capital | – | 2022-06-30 18:00:00 30/06/2022 | – |
| – | RBC Capital | – | 2022-06-21 18:00:00 21/06/2022 | – |
| – | Alan Oscroft | – | 2022-06-14 08:30:00 14/06/2022 | – |
| – | RBC Capital | – | 2022-05-23 09:31:00 23/05/2022 | – |
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
Oxford Biomedica Overview
Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.Latest Oxford Biomedica Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | RBC Capital | – | 2022-07-01 07:13:00 01/07/2022 | – |
| – | RBC Capital | – | 2022-06-30 18:00:00 30/06/2022 | – |
| – | RBC Capital | – | 2022-06-21 18:00:00 21/06/2022 | – |
| – | Alan Oscroft | – | 2022-06-14 08:30:00 14/06/2022 | – |
| – | RBC Capital | – | 2022-05-23 09:31:00 23/05/2022 | – |
Stock Splits and Consolidations
30/05/2018 – Stock Consolidation 50.000:1.000